NOT KNOWN FACTUAL STATEMENTS ABOUT (+)-JQ-1 INHIBITION OF BRD4

For drug discovery aimed at creating second- or 3rd-generation therapeutics, 1 could reasonably argue that TID/MoA ought to be acquired early in the process so as to add price, as current treatment options can be found to People in will need (Figure one). For Some others, Primarily the neurological and psychiatric conditions for which TID/MoA is a